Q-omics provides the consensus-scored RBBP6 profile across patient tissues and cancer cell-line models. RBBP6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RBBP6 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, RBBP6 protein abundance shows 35,588 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where RBBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBBP6 survival associations across molecular data types. RBBP6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBBP6 RNA expression–survival associations across cancer types. High RBBP6 expression shows unfavorable associations in KIRP, ACC, COAD and UVM, but favorable associations in KIRC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify KIRP as the clearest survival context for RBBP6 RNA expression.
This table summarizes RBBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RBBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBBP6 shows lower tumor expression in THCA and higher tumor expression in LIHC, KIRP, KIRC, CHOL and STAD. The THCA box plot shows higher RBBP6 RNA expression in normal versus tumor tissue (log2 FC = −0.592, t-test p < 0.001).
This table shows molecular features associated with RBBP6 in patient tissues and cancer cell lines. In patient samples, RBBP6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBBP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
